Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Poll|February 3, 2015
Hairy Brownish Patch
This asymptomatic, hyperpigmented lesion was first noted 5 years earlier on the left upper back of a 16-year-old boy. A nevus? Cafe au lait spot?
Advertisement
This asymptomatic, hyperpigmented, hairy lesion is on the left upper back of a 16-year-old boy. The pigmentation was first noted 5 years earlier; the coarse and dark hair confined to the hyperpigmented area had appeared at age 13 years. History and physical examination findings were unremarkable.
What’s your diagnosis?
Advertisement
Related to this article
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Advertisement
Advertisement
Trending on Patient Care Online
1
HIV Testing Before and During PrEP: Getting It Right
2
9 Drugs Approved for Primary Care: Q3 2026
3
Immunizing Against Pain and Fear: Rethinking the Vaccination Experience
4
Starting the HIV PrEP Conversation in Primary Care and Pharmacy
5